Don’t Blame AbbVie Inc (ABBV) for Humira’s Success

Page 1 of 2

Flip to the 2012 financial results for AbbVie Inc (NYSE:ABBV) and you’ll see that its best-selling drug, Humira, brought in $9.27 billion in 2012, or 51% of the company’s total revenue. AndroGel, soon to be the second-best-selling drug, reeled in just $1.19 billion in sales. First place never seemed so far away.

Such an eye-popping dependence on one drug gives investors the right to be concerned about AbbVie Inc (NYSE:ABBV)’s susceptibility to volatility. Humira may have double-digit growth ahead of it for 2013, but most of the gains are expected to offset declines from other top drugs. Do investors own the right to hit the panic button?

AbbVie Inc (NYSE:ABBV)Humira hubris?
Obviously, investors aren’t mad at AbbVie Inc (NYSE:ABBV) for wielding a $10 billion product. Think about it — the drug provides most of the cash flow for the dividend and supports a massive chunk of the company’s market cap. But investors shouldn’t blame the company indirectly for the immunology drug’s wild success either. Consider that even if AndroGel tripled its sales next year (just for argument’s sake) Humira would still outsell it three to one. Translation: aAny number looks small compared to $10 billion.

To illustrate that point further, let’s try another fun experiment. If we take the top drugs of other big pharma companies out of their lineup and insert Humira, they, too, would have been overwhelmingly dependent on the drug in 2012. For instance, Bristol Myers Squibb Co. (NYSE:BMY) would have depended on Humira for 38.5% of its sales if we swapped out Abilify.

Company Top-selling drug, % of total 2012 sales Humira swap, % of total 2012 sales No. 2 drug, % of total 2012 sales
Bristol Myers Squibb Co. (NYSE:BMY) Abilify, $2.83 billion, 16% $9.27 billion, 38.5% Sustiva, 6.35%
Johnson & Johnson (NYSE:JNJ) Remicade, $6.14 billion, 24% $9.27 billion, 36.5% Velcade, 5.92%
Merck & Co., Inc. (NYSE:MRK) Januvia/Janumet, $5.74 billion, 14% $9.27 billion, 26.6% Zetia, 7.36%

Source: Company earnings releases. Note: Last column accounts for Humira swap.

This isn’t meant to bring the other companies down; it’s just meant to be a simple way to illustrate that Humira would pose similar challenges to others pharmaceutical firms. I’ll be honest; I don’t know much about Bristol, but Johnson & Johnson and Merck have pretty robust product lineups and pipelines. So in terms of marketed drugs, AbbVie Inc (NYSE:ABBV) is at least one step below its peers. In fact, it is possible that the company will not have a blockbuster outside of Humira and AndroGel at the end of 2013. Ouch.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!